In collaboration with the lab of Dr. Maria J. Vicent at the Principe Felipe Research Center in Valencia, Spain, we report development of a new peptide-guided nanosystem called "OximUNO". OximUNO, by removing the mannose receptor-positive macrophages from the tumor, was safe and effective in treating triple negative breast cancer in mice. OximUNO comprises a star-shaped polyglutamate (St-PGA) decorated with the CD206-targeting peptide mUNO that carries the chemotherapeutic drug doxorubicin (DOX). In the TNBC model, a fluorescently labelled mUNO-decorated St-PGA homed to CD206+ TAMs within primary lesions and metastases. OximUNO exhibited no acute liver or kidney toxicity in vivo. Treatment with OximUNO reduced the progression of primary tumour lesions and pulmonary metastases, significantly diminished the number of CD206+ TAMs and increased the CD8/FOXP3 expression ratio (indicating immunomodulation). Our findings suggest the potential benefit of OximUNO as a TAM-depleting agent for TNBC treatment. Importantly, our studies also represent a novel design of a peptide-targeted St-PGA as a targeted therapeutic nanoconjugate.

Paper:

https://aacrjournals.org/cancerrescommun/article/doi/10.1158/2767-9764.CRC-22-0043/704874/Depletion-of-Mannose-Receptor-Positive-Tumor

Media:

https://meditsiiniteadused.ut.ee/en/node/139971?fbclid=IwAR0WNBefobanP8t1-pN20NuZKtWPx8tvvZjducvYL52GYhRNysDeUullKUs

https://tervis.postimees.ee/7544640/uus-ravim-voimaldab-tulevikus-loodetavasti-ravida-agressiivset-rinnavahki-edukamalt

https://novaator.err.ee/1608629164/vaike-valgujupp-muutis-vahiravimi-tappisrelvaks

https://www.eurekalert.org/news-releases/956479